AngioDynamics (ANGO): Assessing Valuation After Strong Med Tech Growth and Upbeat Outlook

AngioDynamics (ANGO) caught the market’s attention after reporting first quarter financial results that exceeded expectations. Revenue growth was powered by its Med Tech business, and the company upgraded its outlook for the rest of the year.

See our latest analysis for AngioDynamics.

After surprising the market with quarterly sales growth and an outlook upgrade, AngioDynamics has captured renewed investor interest. The momentum from its Med Tech strength coincides with a steady recovery, as the company’s 1-year total shareholder return of just under 1% signals gradual progress after several challenging years and recent headline events.

If Med Tech’s rally has you curious about other innovative healthcare names, it is a great moment to explore opportunities with our See the full list for free.

With shares rallying on upbeat guidance and a narrowing loss, investors now face a pivotal question: Is AngioDynamics actually undervalued after its recent gains, or is the market already pricing in all the future growth?

Most Popular Narrative: 36.2% Undervalued

Compared to AngioDynamics’ last close of $11.64, the most widely followed narrative places fair value much higher, suggesting substantial upside if the outlook holds. This perspective leans heavily on accelerating global demand and significant innovation emerging from the Med Tech portfolio.

The expanding footprint in international markets, recently bolstered by CE Mark approval for Auryon and AlphaVac, opens up new high-growth geographies and distribution channels. This supports sustained double-digit Med Tech segment growth and provides additional sources of revenue diversification.

Read the complete narrative.

Want to know what drives this bullish view? The central force behind the valuation hinges on future growth rates and the optimism surrounding new profit milestones never seen in AngioDynamics’ recent history. Find out which forecasts are bold enough to justify that aggressive target and explore how analysts connect revenue expansion and profit transformation for a Med Tech story the market might be missing.

Result: Fair Value of $18.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, lingering regulatory delays or unexpected tariff hikes could undermine the optimistic scenario. These factors may restrict revenue growth and put pressure on future profit margins.

Find out about the key risks to this AngioDynamics narrative.

Build Your Own AngioDynamics Narrative

If this perspective does not fit your outlook or you would rather dig into the data yourself, you can easily craft a customized narrative in just a few minutes using Do it your way.

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding AngioDynamics.

Looking for More Smart Investment Opportunities?

Shape your portfolio decisively this year. Miss out and you might overlook powerful growth stories, cash-flow bargains, or specialized tech trends reshaping tomorrow’s markets.

• Catch fast-growing potential by jumping into these 24 AI penny stocks where the latest artificial intelligence ideas are turning bold vision into standout returns.
• Seize undervalued opportunities with these 896 undervalued stocks based on cash flows and position yourself ahead before wider market optimism catches on.
• Accelerate your search for passive income with these 19 dividend stocks with yields > 3% offering steady yields above 3% from companies with proven records and strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com